NO – Idenix v. Gilead

Posted: July 21st, 2016

Idenix Pharmaceuticals, Inc. together with Centre National de la Recherche Scientifique, Università degli Studi di Cagliari and L’Université Montpellier II were the proprietors of Norwegian patent NO 330 755. The patent was directed to certain nucleoside analogues with anti-viral activity. Amongst the compounds covered by NO 330 755 was sofosbuvir which is the active ingredient […]


UK – GlaxoSmithKline v Wyeth Holdings

Posted: May 20th, 2016

GlaxoSmithKline UK Limited v Wyeth Holdings LLC, High Court of Justice of England & Wales (Patents Court), London, UK, Carr J, 12 May 2016, Neutral Citation Number: [2016] EWHC 1045 (CH) Carr J has upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein […]


NL – Ajinomoto v. Global Bio-Chem

Posted: May 3rd, 2016

Ajinomoto Co. Inc. and Ajinomoto Eurolysine A.S. v. Global Bio-Chem Technology Group Company Limited et al., Court of Appeal the Hague, the Netherlands, 26 April 2016, Case No. 200-161.842/01 Ajinomoto appealed the judgment in which the District Court (in the counterclaim) invalidated Ajinomoto’s patent EP 1664318 relating to the the production of L-lysine and in […]


UK – Regeneron v. Kymab and Novo Nordisk

Posted: February 16th, 2016

Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S, High Court of England and Wales (Carr J), London, UK, 1 February 2016, Neutral Citation Number: [2016] EWHC 87 (Pat).  On 3 February 2016 the Patents Court (Carr J) held that the disputed claims of two of Regeneron’s patents relating to transgenic mice used for […]


UK – Actavis v. Eli Lilly

Posted: December 7th, 2015

Actavis Group PTC EHF & Anor v Eli Lilly and Company, High Court of England and Wales (Carr J), London, UK, 16 November 2015, Neutral Citation Number: [2015] EWHC 3294 (Pat) This was an action by Actavis to “clear the way” in relation to atomoxetine, the first non-stimulant to be approved for the treatment of […]


UK – Synthon v. Teva

Posted: June 10th, 2015

Synthon v Teva,  London, UK, 21 May 2015, [2015] EWCH 1395 (Pat) Birss J In his judgment of 21 May 2015, Birss J upheld the validity a number of claims of EP’528 and EP’924, both owned by Teva and relating to glatiramer acetate (“GA”).  This was so notwithstanding that the Dutch designations of the same […]


UK – Idenix v. Gilead

Posted: January 5th, 2015

Idenix Phamaceuticals, Inc v Gilead Sciences, Inc and Gilead Sciences Ltd and Centre National de la Recherche Scientifique and Universita Degli Studi de Cagliari and L’Universite Montpellier II, Patents Court, Neutral Citation Number: [2014] EWHC 3916 (Pat) The UK Patents Court has held, in a judgment handed down on 1 December 2014, that European Patent […]


UK – Eli Lilly v Janssen Alzheimer Immunotherapy

Posted: July 8th, 2013

Eli Lilly v Janssen Alzheimer Immunotherapy, 25 June 2013, Patents Court, UK, Case No. HC11C03400 The UK High Court has held Janssen Alzheimer Immunotherapy’s patent relating to a pharmaceutical composition comprising an antibody for the treatment of Alzheimer’s Disease to be invalid.  The two principal issues before the Court were added matter and insufficiency.  On […]


NL – Ajinomoto v. Global et al.

Posted: April 15th, 2013

Ajinomoto v. Global Bio-Chem Technology, Helm et all. District Court The Hague, The Netherlands, 20 March 2013, Case No. C/09.268116 / HA ZA 06-2131 Ajinomoto is the proprietor of EP 0 796 912 relating to a “novel lysine decarboxylase gene and process for producing L-lysine”. Both Ajinomoto and defendants Global et al. produce and sell […]